UK markets open in 32 minutes

NIKKEI 225
40,585.26
+510.57(+1.27%)
HANG SENG
17,961.36
+192.22(+1.08%)
CRUDE OIL
83.15
+0.34(+0.41%)
GOLD FUTURES
2,344.40
+11.00(+0.47%)
DOW
39,331.85
+162.33(+0.41%)
Bitcoin GBP
48,145.32
-1,426.33(-2.88%)

How to make sure you don’t get underpaid when it comes to state pension

Getting less than you were expecting could come as a nasty surprise but there are things you can do about it

IMTX Dec 2025 12.500 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

3.7000

0.0000

(0.00%)

At close: 03:48PM EDT

Simply Wall St.
Here's Why Immatics N.V.'s (NASDAQ:IMTX) CEO Compensation Is The Least Of Shareholders' Concerns
Key Insights Immatics' Annual General Meeting to take place on 20th of June Total pay for CEO Harpreet Singh includes...
Simply Wall St.
Here's Why We're Not Too Worried About Immatics' (NASDAQ:IMTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Globe Newswire
Immatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profileRegistration-enabling